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Background: Alpha-synuclein is a constituent of Lewy bodies and mutations of its 
gene cause familial Parkinson’s disease (PD). A previous study showed that a variant 
of the alpha-synuclein gene (SNCA), namely the 263 bp allele of Rep1 was associated 
with faster motor progression in PD. On the contrary, a recent report failed to detect a 
detrimental effect of Rep1 263 on both motor and cognitive outcomes in PD. Aim of this 
study was to evaluate the influence of the Rep1 variants on disease progression in PD 
patients.
Methods: We recruited and genotyped for SNCA Rep1 426 PD patients with age at 
onset ≥40 years and disease duration ≥4 years. We then analyzed frequency and time of 
occurrence of wearing-off, dyskinesia, freezing of gait, visual hallucinations, and demen-
tia using a multivariate Cox’s proportional hazards regression model.
results: SNCA Rep1 263 carriers showed significantly increased risk of both dementia 
(HR = 3.03) and visual hallucinations (HR = 2.69) compared to 263 non-carriers. Risk of 
motor complications did not differ in the two groups.
conclusion: SNCA Rep1 263 allele is associated with a worse cognitive outcome in PD.
Keywords: dementia, hallucinations, genetic markers, disease progression, Parkinson’s disease
inTrODUcTiOn
Parkinson’s disease (PD) is the second most frequent neurodegenerative disease (1), and is clini-
cally characterized by the presence of asymmetric motor signs, including resting tremor, rigidity, 
and bradykinesia (2). Nonetheless, non-motor symptoms, such as mood deflection, anosmia, and 
sleep disturbances may also be present and can at times pre-date motor impairment (3). As disease 
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progresses, further disabling symptoms appear, such as posture 
and gait impairment on the motor side, and cognitive decline and 
hallucinations in the non-motor domain (4, 5).
Parkinson’s disease neuropathology is characterized by the 
loss of dopaminergic neurons and the presence of Lewy bodies 
(LBs) in surviving neurons (6, 7). LBs contain fibrils composed of 
alpha-synuclein, a small protein involved in synaptic vesicle traf-
ficking and neurotransmitter release (7), but also in more wide-
spread functions, including the triggering of neuroinflammatory 
processes (8). Duplication and triplication of alpha-synuclein 
gene (SNCA) cause dominant early-onset PD, suggesting that 
overexpression of wild-type alpha-synuclein is sufficient to cause 
the disease (9). The amount of alpha-synuclein is relevant in spo-
radic disease as well, since its expression is higher in brain tissue 
from PD patients compared to control tissue (10). Furthermore, 
genome-wide association studies revealed that SNCA variations 
are associated with sporadic PD development (11).
Variations in the complex microsatellite D4S3481 (known as 
Rep-1), located approximately 10 kb upstream of the translational 
start of SNCA, have been reported to increase PD risk. SNCA Rep1 
is essentially triallelic (259, 261, and 263 base pairs in length) and 
a meta-analysis of association studies showed higher frequency 
of 263 bp allele in cases compared to controls (12). Furthermore, 
the 259 bp allele was found to be associated with a decreased risk 
of PD, being more frequent in controls than in cases, whereas no 
relevant effect was observed for the 261 bp allele (12). To date, 
data on the role of SNCA common variants in PD progression 
are conflicting. Ritz et  al. analyzed 232 PD patients and found 
that the risk of faster motor decline, assessed by UPDRS, was 
fourfold increased in carriers of the Rep1 263 bp promoter vari-
ant (13). Thereafter, a study in which outcome was measured in 
terms of life expectancy, did not detect any association between 
SNCA Rep1 genotypes and risk of death in 6,154 PD cases (14). 
More recently, Markopoulou et al. (15) analyzed the correlation 
between SNCA Rep1 genotypes and both motor and cognitive 
outcomes, assessed by telephone interview, in a large cohort of PD 
patients. Surprisingly, they found an opposite role of the micro-
satellite variants, with shorter alleles providing worse outcomes.
On this background, the aim of our study was to investigate 
the effect of SNCA Rep1 on disease progression in a cohort of 
Italian PD patients, clinically characterized through the collec-
tion of solid and reliable milestones of disease evolution.
PaTienTs anD MeThODs
Patients
426 patients (249 males) with PD (2) were enrolled according 
to the following inclusion criteria: age at onset ≥40 years, lon-
gitudinal follow-up ≥ 4 years. All patients were of Italian origin 
and were enrolled at the following Movement Disorders Centers: 
(1) University of Piemonte Orientale, Novara, (2) University of 
Insubria, Varese, (3) IRCCS Foundation Ca’ Granda Ospedale 
Maggiore Policlinico, Dino Ferrari Center, Neuroscience 
Section, University of Milan, (4) C. Mondino National Institute 
of Neurology Foundation, IRCCS, Pavia, (5) Parkinson Institute, 
ASST Gaetano Pini-CTO, Milan. The Parkinson Institute cohort 
(144 patients) had been previously analyzed in both a case-control 
study assessing the role of SNCA variants in PD susceptibility (16) 
and in the collaborative GEO-PD study on survival (14).
Patients who had at least one first- or second degree relative 
with a diagnosis of primary parkinsonism, and/or age at onset 
≤50 years and/or peculiar clinical features had been previously 
analyzed to exclude pathogenic mutations of known PD-related 
genes (SNCA, LRRK2, Parkin, PINK1, and DJ-1) according to 
EFNS guidelines (17).
This study was approved by the Ethics Committee of the 
University of Piemonte Orientale (identification code 65/16). 
Patients were included in the study after having read and signed 
an informed consent form for research purpose.
assessment of PD Progression
All recruited patients had been longitudinally evaluated every 
6 months at each center by a team of neurologist’s expert in move-
ment disorders. The mean follow-up duration was 11.3  years. 
Clinical records were retrospectively analyzed taking into con-
sideration only variables that had been assessed in each center. 
Agreement was found on the following parameters: gender, age 
at onset, disease duration, and family history. Furthermore, the 
presence and time of onset of the following motor and non-motor 
complications was recorded: wearing-off, dyskinesia, freezing of 
gait, visual hallucinations, and dementia. Dementia was diag-
nosed with a comprehensive cognitive evaluation according to 
MDS criteria (18).
Determination of SNCA Variants
Genomic DNA was extracted from peripheral blood using stand-
ard procedures. We analyzed the microsatellite SNCA Rep1 in the 
entire cohort (426 subjects). The SNCA Rep1 region was ampli-
fied through PCR from genomic DNA using the primer pair: 
5′-GACTGGCCCAAGATTAACCA-3′ (fluorescently labeled 
with 6-FAM) and 5′-CCTGGCATATTTGATTGCAA-3′. PCR 
products were resolved by capillary electrophoresis on an 
ABI-3130XL DNA Analyzer (Applied Biosystem, Foster City, 
CA, USA) using GeenScan-500 ROX (Applied Biosystem) as 
molecular weight marker. Allelic sizes were assessed using the 
GeneMapper 4.0 software.
To confirm the accuracy of the genotyping method, we 
sequenced several individuals representative of each genotype as 
standard samples.
statistical analysis
Allelic distribution was assessed for Hardy–Weinberg equilib-
rium (HWE) with Fisher’s exact test.
SNCA Rep1 was analyzed using a dominant genetic model 
(e.g., subjects 263 carriers vs 263 non-carriers) as previously 
described (13).
Continuous variables were reported as median and 25th and 
75th percentile, categorical variables were presented as frequen-
cies (counts) and percentages. Allelic frequencies and family 
history were compared with the χ2 test, differences between age 
at onset and disease duration were assessed with Mann–Whitney 
U test.
TaBle 1 | Demographic and clinical features of study population.
n = 426
Male, n, (%) 249 (58.5%)
Age at onset, median (25–75th) 62 (55–68)
Age at assessment, median (25–75th) 74.0 (68–79)
Disease duration, median (25–75th) 11.0 (8–14)
Family history, n, (%) 81 (19.0%)
Wearing-off, n, (%) 231 (54.2%)
Dyskinesia, n, (%) 196 (46.0%)
Freezing of gait, n, (%) 169 (39.7%)
Visual hallucinations, n, (%) 85 (20.0%)
Dementia, n, (%) 77 (18.1%)
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The influence of the SNCA variant carrier status on disease 
natural history was investigated performing time-to-event 
analysis: wearing-off, dyskinesia, freezing of gait, visual hallu-
cinations, and dementia were considered as separate outcomes. 
Every patient contributed time of observation from disease onset 
to complication under study or the last assessment. Individual 
analyses were performed for each complication under study and 
cumulative incidences were estimated using the Kaplan–Meier 
(KM) methods. Log-rank test was used to examine univariate 
association with outcome. Multivariate Cox’s proportional haz-
ards (PHs) regression model was fitted to obtain the hazard ratio 
(HR) for SNCA variant carrier status adjusted by gender, age at 
PD onset, and recruitment center.
Proportional hazard model was assessed by regression scaled 
Schoenfeld residuals against the log time. All p-values are two-
tailed and the significance cut-off was p < 0.05. Statistical analysis 
was performed using STATA v14.
resUlTs
Demographic and clinical features of the 426 PD patients are 
summarized in Table 1.
Observed frequencies of SNCA Rep1 genotypes were in HWE 
(p = 0.19) (Table S1 in Supplementary Material).
Disease duration and family history did not differ significantly 
between Rep1 263 carriers (n = 44) and 263 non-carriers (n = 382) 
(p = 0.088, Mann–Whitney U test, and p = 0.797, χ2 test). On 
the contrary, the former group showed significantly earlier age at 
onset compared to the latter (p = 0.016, Mann–Whitney U test) 
(Table S2 in Supplementary Material).
Furthermore, we performed a Kaplan–Meyer survival analysis 
to compare the probability of developing each complication over 
time in 263 carriers vs 263 non-carriers (Figure 1; Figure S1 in 
Supplementary Material). At 10  years from onset, cumulative 
incidence of dementia was higher in carriers than in non-carriers 
(26.39 vs 12.94%, log-rank test p = 0.001; Table 2). Similar find-
ings were also observed for visual hallucinations and wearing-off 
(24.48 vs 15.01% and 65.33 vs 53.02%, log-rank test p = 0.0037 
and p = 0.028 respectively; Table 2).
Finally, after applying a multivariate Cox regression model 
adjusting by gender, age at disease onset, and recruitment 
center, a statistically significant difference persisted for dementia 
and visual hallucinations, but not for wearing-off. In detail, we 
found that 263 carriers had a 3.03-fold higher risk of dementia, 
a 2.69-fold higher risk of visual hallucinations, and a 1.26-fold 
higher risk of wearing-off compared to non-carriers (p < 0.001, 
p = 0.001, and 0.236, respectively; Table 3).
DiscUssiOn
This study showed for the first time that Rep1 polymorphic vari-
ants of the SNCA gene influence non-motor evolution in PD. In 
patients carrying the SNCA Rep1 263 allele, the risk of developing 
dementia and visual hallucinations is increased by 3.03 and 2.69, 
respectively, compared to patients carrying shorter Rep1 variants. 
With regards to motor progression, Rep1 263 carriers display a 
slightly increased cumulative incidence of wearing-off, compared 
to non-carriers, even though such difference was not statistically 
significant in multivariate regression.
To date, there is strong evidence supporting a genetic 
component in PD susceptibility. On the contrary, few studies 
have addressed the role of disease modifying genes (19, 20, 21). 
This might be due, at least in part, to the difficulty in collect-
ing data on disease evolution compared to recording disease 
development. Consistently, large collaborative studies aimed at 
tracking PD progression are ongoing (22, 23). In our study, we 
chose to include only patients with longitudinal follow-up and 
accurate information regarding the main motor and non-motor 
complications, putting together a well characterized population 
of 426 patients.
The cognitive features of 263 carriers recalled that of familial 
PD caused by rare pathogenic SNCA multiplications, in which 
progression is faster compared to sporadic PD (24). It is known 
that such mutations cause alpha-synuclein overproduction 
through increased mRNA expression (25). With regards to the 
possible effect of the length of Rep1 microsatellite on alpha-
synuclein expression, conflicting data were reported. Chiba-
Falek et  al. detected a threefold increase of alpha-synuclein 
expression with longer compared to shorter Rep1 alleles in a 
cellular model (26). Furthermore, alpha-synuclein mRNA 
varied 1.7-fold in transgenic mice carrying the different Rep1 
alleles (27). These findings were further supported by Fuchs 
et al. who detected a correlation between protein level in blood 
and Rep1 genotypes (28). Intriguingly, a recent report remarked 
that plasma alpha-synuclein levels may predict cognitive decline 
in PD (29). On the contrary, Soldner et al. suggested that neither 
the deletion of the entire Rep1 repeat sequence nor the presence 
of the three different length alleles (including 263 bp) were able 
to influence significantly SNCA expression. Nonetheless, the 
authors themselves underline that their findings might have 
been influenced by the cellular model analyzed, which only 
allows to detect early events (30). For such reasons, a robust 
biologic relationship between the 263 allele and PD progression 
still has to be confirmed.
Our study is the first to investigate the correlation between 
SNCA polymorphisms and PD progression in the European 
population. On the contrary, two Northern American studies, 
the first on 233 patients and the second on 1,098 patients, were 
published in 2012 and 2014, respectively (12, 13).
In the first study, a faster motor progression in PD patients 
carrying at least one Rep1 263 was reported (13). As regards, 
FigUre 1 | Continued
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motor progression in Rep1 263 carriers, our findings display 
a trend similar to that of Ritz et al. (13), even though our data 
lose statistical significance in the multivariate regression model. 
Nonetheless, it should be noted that discrepancies might be 
related to substantial methodological differences. In fact, Ritz 
et  al. (13) studied a cohort of 233 PD patients for a relatively 
short follow-up (5.1  years) and measured motor progression 
with the motor section of UPDRS. This score: (a) Does not weigh 
the different motor signs, (b) does not evaluate cognitive and 
neuropsychiatric complications, (c) is strongly influenced by 
TaBle 3 | Multivariate Cox’s regression model on all study population.
hr (95%ci)a P
Wearing-off 1.26 (0.86–1.86) 0.236
Dyskinesia 0.94 (0.62–1.45) 0.794
Freezing of gait 0.97 (0.61–1.55) 0.901
Visual hallucinations 2.69 (1.57–4.60) 0.001
Dementia 3.03 (1.74–5.30) <0.001
aHazard ratio (HR) of Rep1 263 carriers vs 263 non-carriers.
Data are adjusted by gender, age at PD onset, and recruitment center.
TaBle 2 | Probability of complications at 10 years from disease onset.
rep1 263 carriers % 
at 10 years (95% ci)
rep1 263 non-carriers % 
at 10 years (95% ci)
P*
Wearing-off 65.33 (50.03–80.14) 53.02 (47.47–58.59) 0.028
Dyskinesia 44.10 (29.81–61.55) 44.05 (38.67–49.81) 0.360
Freezing of gait 33.19 (21.07–49.72) 34.25 (29.18–39.92) 0.621
Visual 
hallucinations
24.48 (13.88–40.97) 15.01 (11.50–19.47) 0.004
Dementia 26.39 (15.50–42.72) 12.94 (9.72–17.13) 0.001
*Log-rank test.
FigUre 1 | Kaplan–Meyer survival analysis of complications [dementia panel (a); visual hallucinations panel (B); wearing-off panel (c)].
5
Corrado et al. SNCA Rep1 and PD
Frontiers in Neurology | www.frontiersin.org March 2018 | Volume 9 | Article 213
A second report was published in 2014 by Markopoulou 
et al. (15). In this study, authors failed to detect a detrimental 
effect of Rep1 263 allele on PD progression. On the contrary, 
they found that patients carrying longer Rep1 alleles had a better 
motor outcome and a similar trend was observed for cognitive 
outcome, even though without statistical significance. In this 
case too, important differences between the two studies might 
account for the discordant results. First, our clinical data were 
collected through direct examination of patients, whereas cog-
nitive data included in the report by Markopoulou et  al. (15) 
were collected through telephonic interviews. Second, the bio-
logical effect of Rep1 microsatellite might differ among subjects, 
especially when a different ethnic background is involved. In 
fact, Rep1 is a complex microsatellite characterized by a mixed 
dinucleotide composition. Alleles with the same size could have 
different composition and it was reported that two alleles with 
the same length, but different dinucleotide composition might 
have different functional effects on the promoter activity (26). 
Finally, the way data are presented in the two studies makes 
results difficult to compare. In fact, Markopoulou et  al. (15) 
aggregated patients carrying two different genotypes (261–261 
and 259–263) in a unique very large group, thus losing the 
impact of the 263 allele.
cOnclUsiOn
Our study found a significant and biologically plausible correla-
tion between SNCA Rep1 263 allele and the risk of development 
treatment, and (d) shows a relevant inter-rater variability (31). 
On the other hand, our study of Rep1 SNPs included a larger 
population (426 patients) with a mean follow-up of 11.3 years. 
Progression was measured through clinical milestones, which are 
reliable measures of patients’ status, especially when multicenter 
studies are concerned.
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